Abstract
Ninety-seven patients with impetigo were prospectively enrolled in a study to determine the comparative efficacy of systemic and topical antibiotic therapy. After obtaining a bacterial culture from a representative lesion, the children were randomized to receive seven days of either oral erythromycin or topical mupirocin administered three times daily. Staphylococcus aureus alone was isolated from 51% and in association with group A beta-hemolytic streptococci (GABS) from 29%; GABS alone was isolated from 4% of patients. Of 48 children who received erythromycin, 43 (90%) were clinically improved or cured, and 11 of 17 were bacteriologically cured. Of 49 children who received mupirocin, 47 (96%) were clinically improved or cured, and 10 of 14 were bacteriologically cured. At three-week follow-up, clinical cure rates and number of secondary household cases of impetigo were equivalent in both treatment groups. Mupirocin appears to be a well-tolerated, albeit expensive, alternative to erythromycin for the treatment of impetigo.
References
May 1, 1988·Pediatric Dermatology·L L BartonM G Portilla
Nov 1, 1986·Archives of Dermatology·L D EellsW H Eaglstein
Nov 1, 1986·Drugs·A Ward, D M Campoli-Richards
Jan 1, 1987·The Journal of Antimicrobial Chemotherapy·M W Casewell, R L Hill
Nov 1, 1987·Pediatric Dermatology·L L Barton, A D Friedman
Nov 1, 1988·The Pediatric Infectious Disease Journal·S McLinn
Dec 1, 1988·Antimicrobial Agents and Chemotherapy·J GoldfarbJ L Blumer
Feb 1, 1988·The Journal of Antimicrobial Chemotherapy·A S Malmborg, S Rannikko
Jun 1, 1988·The Journal of Antimicrobial Chemotherapy·R K TuominenH Haataja
Jul 1, 1987·Journal of the American Academy of Dermatology·R J Coskey, L A Coskey
May 1, 1985·The Journal of Antimicrobial Chemotherapy·M W Casewell, R L Hill
Apr 1, 1967·American Journal of Diseases of Children·W T Hughes, R T Wan
Feb 1, 1983·Pediatric Clinics of North America·C W Derrick, K M Reilly
Sep 1, 1983·Antimicrobial Agents and Chemotherapy·J ChirifeE S Kohn
Apr 1, 1983·Pediatric Clinics of North America·L SchachnerM Morrison
Jan 10, 1963·The New England Journal of Medicine·J W BURNETT
Sep 17, 1949·Journal of the American Medical Association·J L DERZAVISL S LELAND
Citations
Feb 9, 1999·The Journal of Emergency Medicine·P M Williford
Feb 15, 2001·Clinics in Dermatology·I OumeishO Bataineh
Jan 16, 1992·The New England Journal of Medicine·T J Phillips, J S Dover
Feb 1, 1997·The Pediatric Infectious Disease Journal·G L Darmstadt
Jul 1, 1997·The Pediatric Infectious Disease Journal·J W BassS N Marks
Jan 1, 1992·International Journal of Dermatology·J H Booth, S I Benrimoj
Dec 1, 1994·Pediatric Dermatology·G L Darmstadt, A T Lane
Mar 1, 1995·Pediatric Dermatology·M L MiskoD G Diven
Feb 1, 1992·Antimicrobial Agents and Chemotherapy·R Dagan, Y Bar-David
Oct 3, 1999·Journal of Accident & Emergency Medicine·J McVicar
May 6, 2005·Paediatric Drugs·Shamez Ladhani, Mehdi Garbash
Oct 19, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dennis L StevensUNKNOWN Infectious Diseases Society of America
Apr 1, 1993·Pediatric Annals·R Dagan
Aug 1, 1990·Journal of the American Academy of Dermatology·R J Coskey
Nov 1, 1990·The Journal of Pediatrics·J W BrittonB Krafte-Jacobs
Sep 1, 1992·Clinical Pediatrics·J J Leyden
May 8, 1992·PharmacoEconomics·N H Holford
Jan 20, 2012·The Cochrane Database of Systematic Reviews·Sander KoningJohannes C van der Wouden
Oct 7, 2009·Expert Review of Anti-infective Therapy·Ronald PangilinanGlenn Tillotson
Dec 19, 2020·Antibiotics·Solomon AbrhaJackson Thomas
Oct 30, 2020·Pharmaceuticals·Nicola PrincipiSusanna Esposito
Jun 1, 2000·Infectious Disease Clinics of North America·E T Kaye